WHO ICTRP trial
A Phase 1 Randomized, Double-Blind and Paralle, Controlled Single-dose Clinical…
ChiCTR1900022127 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR1900022127 |
|---|---|
| Public title | A Phase 1 Randomized, Double-Blind and Paralle, Controlled Single-dose Clinical Trial of Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of QX001S and Stelara in Chinese Health Male Subjects |
| Scientific title | A Phase 1 Randomized,Double-Blind and Paralle, Controlled Single-dose Clinical Trial of Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of QX001S and Stelara in Chinese Health Male Subjects |
| Primary sponsor | JiangSu Qyuns Therapeutics Co., Ltd |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional study |
| Phase | 1 |
| Countries | China |
| Conditions | Moderate to severe plaque psoriasis in adults |
| Interventions | QX001S versus ustekinumab:QX001S injection, 45 mg (0.5 mL, QX001S, 45 mg (0.5 mL), Ustekinumab 45 mg (0.5 mL), 45 mg (0.5 mL) |
| Registration date | Mar 26, 2019 |
| Target size | QX001S versus ustekinumab:178 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: